Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

7.2 (USD) • At close September 19, 2024
Bedrijfsnaam Aurinia Pharmaceuticals Inc.
Symbool AUPH
Munteenheid USD
Prijs 7.2
Beurswaarde 1,029,535,200
Dividendpercentage 0%
52-weken bereik 4.71 - 10.05
Industrie Biotechnology
Sector Healthcare
CEO Mr. Peter S. Greenleaf M.B.A.
Website https://www.auriniapharma.com

An error occurred while fetching data.

Over Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka

Vergelijkbare Aandelen

BioCryst Pharmaceuticals, Inc. logo

BioCryst Pharmaceuticals, Inc.

BCRX

8.15 USD

SpringWorks Therapeutics, Inc. logo

SpringWorks Therapeutics, Inc.

SWTX

35.35 USD

Apollo Medical Holdings, Inc. logo

Apollo Medical Holdings, Inc.

AMEH

40.82 USD

Fulgent Genetics, Inc. logo

Fulgent Genetics, Inc.

FLGT

22.89 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)